Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2019 Genitourinary Cancers Symposium /
KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

14th - 16th Feb 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.02.19
Views: 601
Rating:

Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Prof David McDermott speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about results from cohort B of the KEYNOTE-427 study looking at first-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma.

He explains that, compared to clear cell patients, non-clear cell patients don't tend to have many therapies available and have been excluded from most of the immune therapy trials due to a historically poor response to cytokine therapy.

Prof McDermott reports activity was seen and that there was an overall response of 25% with particular favourability in the papillary and unclassified histology groups.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation